Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any hereditary spherocytosis in which the cause of the disease is a mutation in the EPB42 gene.
Features include always present findings: Increased immature red blood cells (reticulocytosis), Enlarged spleen (splenomegaly), and Jaundice. 8 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 5 | Abnormal leukocyte count, Red blood cell destruction (hemolytic anemia), Increased immature red blood cells (reticulocytosis) |
Digestive system | 2 | Enlarged spleen (splenomegaly), Jaundice |
Children with EPB42-related hereditary spherocytosis (EPB42-HS) frequently present within the first 24 hours of life with jaundice that requires treatment with phototherapy or, rarely, exchange transfusion to prevent kernicterus. They may also present later in childhood with anemia resulting from a hemolytic crisis or aplastic crisis usually associated with a viral infection. Toddlers with hereditary spherocytosis are occasionally found to have age-related iron deficiency anemia; however, the anemia fails to completely resolve with iron supplementation and reticulocytosis persists . As with all forms of mild or moderate hereditary spherocytosis (see for definitions), EPB42-HS can be more severe in the first four to six months of life, requiring regular red blood cell transfusions.
Source: GeneReviews — "EPB42-Related Hereditary Spherocytosis"
EPB42 encodes erythrocyte membrane protein band 4.2 (691 aa). Component of the ankyrin-1 complex, a multiprotein complex involved in the stability and shape of the erythrocyte membrane Highest expression in Whole Blood (29.0 TPM) and Testis (6.0 TPM).
Hereditary spherocytosis type 5 is associated with mutations in the EPB42 gene on chromosome 15.
EPB42 is classified as a druggable target (Druggable Genome category) with score 0.0.
Suggestive Findings EPB42-related hereditary spherocytosis (EPB42-HS) should be suspected in individuals with any of the following clinical and laboratory findings. Clinical findings • Pallor and/or fatigue due to anemia, which is usually of mild-to-moderate severity • Jaundice • Usually intermittent and caused by unconjugated hyperbilirubinemia resulting from exacerbated hemolysis • In rare instances, caused by conjugated hyperbilirubinemia resulting from biliary obstruction • Splenomegaly • Cholelithiasis in the second or third decade of life Laboratory findings • Complete blood count consistent with: • Chronic, nonimmune hemolytic anemia (decreased hemoglobin [Hgb] with reticulocytosis), usually of mild-to-moderate severity • Decreased Hgb level (See for Hgb levels that define the severity of hereditary spherocytosis.) Note: Hgb values in EPB42-HS may also vary depending on the clinical status of the affected individual (baseline or during a hemolytic or aplastic crisis). • Increased percent of reticulocytes as well as increased absolute reticulocyte count (See for percent of reticulocytes that define the severity of hereditary spherocytosis.) Note: Percent of reticulocytes may vary (depending on baseline or crisis status) from 2.5% to greater than 10% (or even normal or low when in aplastic crisis). • High mean corpuscular Hgb concentration. Normal values are typically 31-37 g/dL. Values in individuals with hereditary spherocytosis are usually 35.5-37.5 g/dL. • Negative (i.e., normal) direct anti-globulin test (DAT) Note: DAT should always be evaluated in a person with newly diagnosed hemolytic anemia to evaluate for an acute immune-mediated (acquired) hemolytic anemia. • Peripheral blood smear demonstrating presence of spherocytes and occasionally a few ovalocytes and elliptocytes Note: The term "spherocyte" refers to the sphere-shaped red blood cells (with a decreased surface-to-volume ratio) that characterize the red blood cell membrane skeleton disorders . • Significantly decreased or absent haptoglobin. After age six months normal haptoglobin values are 16-200 mg/dL. In hereditary spherocytosis, haptoglobin is typically undetectable; however, haptoglobin can be normal in the presence of concurrent inflammation (as it is an acute phase reactant). • Mildly increased osmotic fragility (as in Figure 1B of ; see full text) • Decreased maximal deformability index (DImax; also known as elongation index, or EImax) and increased Omin (osmolality at which 50% of red blood cells hemolyze) measured by osmotic gradient ektacytometry, giving a typical hereditary spherocytosis curve Family history is consistent with autosomal recessive inheritance (e.g., affected sibs and/or parental consanguinity). Absence of a known family history does not preclude the diagnosis. Table 1. Severity of Hereditary Spherocytosis
Severity | Hgb (g/dL) | Reticulocytes | Splenectomy |
|---|---|---|---|
Mild | 11-15 | 3%-8% | Not necessary |
Moderate | 8-11.5 | 8% | Consider if activity level quality of life |
Moderately severe | 6-8 | ≥10% | Indicated at age 5 yrs |
Severe | 6 | ≥10% | Indicated at age 3 yrs |
Source: GeneReviews — "EPB42-Related Hereditary Spherocytosis"
Genetic testing for EPB42 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hereditary spherocytosis type 5 has been reported in the published literature.
No approved treatments are currently available for hereditary spherocytosis type 5. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with EPB42-related hereditary spherocytosis (EPB42-HS), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with EPB42-Related Hereditary Spherocytosis
System/Concern | Evaluation | Comment |
|---|---|---|
Hyperbilirubinemia | Serum bilirubin concentration | Anemia |
Iron overload | Serum ferritin concentration | — |
Cholelithiasis | Abdominal ultrasound exam to assess for cholelithiasis | In those w/signs/symptoms of cholelithiasis or beginning at age 10-12 yrs in those w/significant hemolysis |
Splenomegaly | Abdominal ultrasound exam to evaluate spleen size | If physical exam is not conclusive due to body habitus or if contact sports are contemplated |
Genetic counseling | By genetics professionals1 | To inform affected persons their families re nature, MOI, implications of EPB42-HS to facilitate medical personal decision making EPB42-HS = EPB42-related hereditary spherocytosis; MOI = mode of inheritance 1. |
Source: GeneReviews — "EPB42-Related Hereditary Spherocytosis"
View trials for hereditary spherocytosis type 5
Table 6. Recommended Surveillance for Individuals with EPB42-Related Hereditary Spherocytosis
System/Concern | Evaluation | Frequency |
|---|---|---|
Hyperbilirubinemia | Serum bilirubin concentration | Monitor in neonates during 1st wk of life.; If persistently , consider possibility of concurrent Gilbert syndrome, which s risk for early development of cholelithiasis. |
Anemia | Hemoglobin | Monitor in infants in 1st 2-4 mos of life, then as needed depending on degree of anemia disease severity. |
Iron overload | Serum ferritin concentration | At least annually in those requiring frequent transfusions; In those on chelation, monitor ferritin values every 3-4 mos. T2*-weighted MRI or FerriScan® |
Cholelithiasis | Abdominal ultrasound exam | When signs/symptoms of cholelithiasis develop or every 5-10 yrs beginning at age 10-12 yrs in those w/significant hemolysis |
Source: GeneReviews — "EPB42-Related Hereditary Spherocytosis"
Phenotype severity distribution: 3 always present features.
No clinical trials have been registered for hereditary spherocytosis type 5.
49 publications have been identified in PubMed for hereditary spherocytosis type 5. Research spans Case Report / Case Series (35%), Epidemiology / Natural History (20%), and Diagnostic / Biomarker (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 17 | 35% |
Disease patterns and progression | 10 | 20% |
Testing and diagnosis research | 9 | 18% |
Laboratory research | 5 | 10% |
Research summaries | 4 | 8% |
Clinical study results | 3 | 6% |
Other research | 1 | 2% |
Kim HJ (2026). [PMID: 42148170](https://pubmed.ncbi.nlm.nih.gov/42148170/). *Pediatr Gastroenterol Hepatol Nutr*. [Diagnostic / Biomarker]
Kajitani K (2026). [PMID: 42015925](https://pubmed.ncbi.nlm.nih.gov/42015925/). *Small*. [Basic Science / Preclinical]
Mo Y (2026). [PMID: 41834204](https://pubmed.ncbi.nlm.nih.gov/41834204/). *Zhonghua Er Ke Za Zhi*. [Diagnostic / Biomarker]
de Wilde JRA (2026). [PMID: 41914049](https://pubmed.ncbi.nlm.nih.gov/41914049/). *Br J Haematol*. [Basic Science / Preclinical]
Abdelhafeez AH (2026). [PMID: 41852320](https://pubmed.ncbi.nlm.nih.gov/41852320/). *Pediatr Blood Cancer*. [Case Report / Case Series]
Chakraborty A (2026). [PMID: 42054241](https://pubmed.ncbi.nlm.nih.gov/42054241/). *J Pediatr Hematol Oncol*. [Epidemiology / Natural History]
Biaggioni PA (2026). [PMID: 42046260](https://pubmed.ncbi.nlm.nih.gov/42046260/). *Eur J Haematol*. [Diagnostic / Biomarker]
Ryu H (2025). [PMID: 41253467](https://pubmed.ncbi.nlm.nih.gov/41253467/). *Ann Clin Lab Sci*. [Diagnostic / Biomarker]
Cheng J (2025). [PMID: 39995895](https://pubmed.ncbi.nlm.nih.gov/39995895/). *Front Pediatr*. [Epidemiology / Natural History]
Pegu B (2025). [PMID: 40880585](https://pubmed.ncbi.nlm.nih.gov/40880585/). *Obstet Med*. [Case Report / Case Series]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 6:54 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
11.7-15.7 (adult females)13.3-17.7 (adult males) |
0.5%-1.5%2 |
Hgb = hemoglobin Based on table by 1. Normal values may vary somewhat depending on age and sex. 2. Absolute reticulocyte count = 45-90 x 103/L Establishing the Diagnosis The diagnosis of EPB42-HS is established in a proband by the identification of biallelic pathogenic variants in EPB42 . |
Treatment of Manifestations in Individuals with EPB42-Related Hereditary Spherocytosis Manifestation/Concern | Treatment | Considerations/Other |
Iron overload | Strongly consider treatment w/iron chelator if child remains transfusion dependent after 1st yr of life. Monitor ferritin obtain T2*-weighted MRI to determine hepatic iron levels if ferritin remains steadily (300-500 ng/mL). | Splenomegaly |